Title : A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

Pub. Date : 2021 Feb 24

PMID : 33627685






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. olaparib BRCA1 DNA repair associated Homo sapiens